Prognosis and survival for penile cancer

Last medical review:

A prognosis is the doctor’s best estimate of how cancer will affect you and how it will respond to treatment. Survival is the percentage of people with a disease who are alive at some point in time after their diagnosis. Prognosis and survival depend on many factors, including certain aspects of the cancer (such as its stage) as well as characteristics of the person (such as their age and family history). These are called prognostic factors.

Only a doctor familiar with your medical history, the type and stage and other features of the cancer, the treatments chosen and the response to treatment can put all of this information together with survival statistics to arrive at a prognosis and chances of survival.

The following are prognostic factors for penile cancer.

Stage

The most important prognostic factor for penile cancer is its stage. Penile cancer that is diagnosed at an early stage has a better prognosis than penile cancer that is diagnosed in advanced stages (the cancer has spread to nearby lymph nodes or other organs).

Spread to lymph nodes in the groin

For penile cancer that has spread to lymph nodes in the groin (inguinal lymph nodes), cancer that has spread to only one lymph node has a better prognosis than cancer that has spread to more than one lymph node.

Tumour size

For penile cancer that has not spread to lymph nodes or other organs, tumours that are 3 cm or larger have a poorer prognosis than tumours smaller than 3 cm.

Grade

Lower grade penile cancers usually have a better prognosis than those with a higher grade. Tumours on the foreskin or the head of the penis (glans) tend to be lower grade. Tumours that affect the shaft of the penis tend to be a higher grade.

Association with HPV infection

Human papillomavirus (HPV)- associated squamous cell carcinoma (SCC) of the penis tends to have a better prognosis than HPV-independent SCC.

Expert review and references

  • Di (Maria) Jiang, MD, MS, FRCPC
  • Li K, Wu G, Fan C, Yuan H. The prognostic significance of primary tumor size in squamous cell carcinoma of the penis. Discover Oncology. 2021: 12:22.
  • National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Penile Cancer Version 2.2025. 2025. https://www.nccn.org/home.
  • Pettaway CA, Srigley JR, Brookland RK, et al. Penis. Amin MB (ed.). AJCC Cancer Staging Manual . 8th ed. Chicago, IL: American College of Surgeons; 2017: 57:709–722.
  • Sand FL, Rasmussen CL, Frederiksen MH, Andersen KK, Kjaer SK. Prognostic Significance of HPV and p16 Status in Men Diagnosed with Penile Cancer: A Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers & Prevention. 2018: 27(10):1123–1132.

Survival statistics for penile cancer

Survival statistics for penile cancer are very general estimates. Survival is different for each stage and type of tumour.

Your trusted source for accurate cancer information

With support from readers like you, we can continue to provide the highest quality cancer information for over 100 types of cancer.

We’re here to ensure easy access to accurate cancer information for you and the millions of people who visit this website every year. But we can’t do it alone.

Every donation helps fund reliable cancer information, compassionate support services and the most promising research. Please give today because every contribution counts. Thank you.

Medical disclaimer

The information that the Canadian Cancer Society provides does not replace your relationship with your doctor. The information is for your general use, so be sure to talk to a qualified healthcare professional before making medical decisions or if you have questions about your health.

We do our best to make sure that the information we provide is accurate and reliable but cannot guarantee that it is error-free or complete.

The Canadian Cancer Society is not responsible for the quality of the information or services provided by other organizations and mentioned on cancer.ca, nor do we endorse any service, product, treatment or therapy.


1-888-939-3333 | cancer.ca | © 2026 Canadian Cancer Society